一字涨停！亚太药业易主，公司回应新东家溢价45%接盘

Core Viewpoint - Asia-Pacific Pharmaceutical (002370.SZ), a long-established pharmaceutical company, experienced a surge in stock price despite ongoing losses, closing at 6.24 CNY per share after a trading halt, with a total trading volume of 355 million CNY. This follows the announcement of a share transfer agreement with a new controlling shareholder, Star Holdings, at a significant premium price [1]. Group 1: Share Transfer Agreement - The controlling shareholder, Fubon Group, and its associates signed a share transfer agreement with Star Holdings and its associates on October 13, transferring 14.61% of Asia-Pacific Pharmaceutical's shares (approximately 109 million shares) at a price of 8.26 CNY per share [1]. - The total transaction amount reached 900 million CNY, representing a premium of 45.68% over the closing price of 5.67 CNY per share prior to the trading halt [1]. - Following the transaction, the controlling shareholder of Asia-Pacific Pharmaceutical will change to Star Holdings, with the actual controller becoming Qiu Zhongxun [1]. Group 2: Industry Context - Asia-Pacific Pharmaceutical operates in the biopharmaceutical industry, which is characterized by high professional barriers [1]. - The new shareholder is reported to have a certain background in the pharmaceutical sector, which may influence the company's future direction and strategy [1]. - The original shareholders have their own plans, and the transaction price was a result of negotiations between the new and old shareholders, although comments on the premium were not provided [1].